Video
Dr. Srinivasan on VHL-associated RCC prognosis and treatment
Author(s):
Ramaprasad Srinivasan, MD, PhD, provides background on the prognosis and treatment of patients with Von Hippel-Lindau–associated renal cell carcinoma and highlights the novel agent MK-6482.
Ramaprasad Srinivasan, MD, PhD, Urologic Oncology Branch, National Cancer Institute, provides in-depth background of the prognosis and treatment development for Von Hippel-Lindau (VHL)–associated renal cell carcinoma (RCC).
During the 2020 Society of Urologic Oncology Annual Meeting, Srinivasan shared results from a phase 2 study of the investigational HIF-2α inhibitor MK-6482 in patients with VHL–associated RCC. At a median follow-up of 68.7 weeks (range, 18.3-104.7), the objective response rate in RCC lesions among 60 evaluable patients was 36.1%, comprising 22 confirmed partial responses. There were also 7 unconfirmed PRs. Overall, 91.8% (n = 56) of patients had at least some decrease in the size of target lesions.
